Ultragenyx Analyst Day Presentation slide image

Ultragenyx Analyst Day Presentation

CRYSVITA® Exclusivity summary United States XLH Orphan Exclusivity TIO Orphan Exclusivity Biologics Exclusivity Crysvita COM Patent Q2W Dosing Patent 2025 2027 2030 2032* 2035 CRYSVITA burosumab 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 Europe *Includes projected US PTE and EU SPC awards 22 Confidential and Proprietary 2028 XLH Orphan D&M Exclusivity -- 2033* Crysvita COM Patent 2035 Q2W Dosing Patent ultragenyx
View entire presentation